This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Supply chain shortages have dominated headlines for several months, and the pharma industry has been no exception. The pandemic effectively shut down supply chain paths overnight, and as a result, pharmaceuticalmanufacturers have faced delays and bottlenecks, which have caused drug shortages in healthcare systems.
The pharmaceutical supply chain is a global and complex network that includes a wide range of stakeholders such as pharmaceuticalmanufacturers, wholesale distributors, and pharmacy benefit managers (PBM), to ensure efficient and timely delivery of medications to the patients. Rise of pharma cold chain logistics companies.
The end-to-end supply chain comprises material procurement, manufacturing, transportation, warehousing, and distribution. For pharmaceuticalmanufacturing, many of these processes are subject to good manufacturing practice (GxP) and oversight by regulatory bodies.
When people think about pharma, they often think about “big” pharma: large, faceless corporations. The status isn’t awarded lightly and Chiesi is the largest pharmaceuticalmanufacturer to be named a B Corp. “We But rare diseases are a particularly important and challenging focus area.
Recommendations were also published earlier this year for all stakeholders in the pharma supply chain. In this Q&A EPR speaks to Naser Al Yammahi the Deputy CEO of Hayat Biotech about pharmaceutical supply chain challenges and how they can be addressed. What types of medicinal products are in short supply and why?
The Grand View Research published a report highlighting the stark growth prospects of the pharma industry. The global pharmaceuticalmanufacturing market stood at USD 405.52 The paradigm shift towards integrated, intelligent, and data-rich technologies is propelling the growth of medicines manufacturing. Let’s find out!
Pharmaceutical wholesalers act as intermediaries between pharmaceuticalmanufacturers and retailers and facilitate the delivery of the right medicines in a timely, efficient, and secure manner. The post Leading pharmaceutical wholesalers appeared first on Pharmaceutical Technology.
Freeze-drying systems companies help in the verification and validation monitoring of the freeze-drying process to comply with the latest regulations and good automated manufacturing practice (GAMP) guidelines. The companies offer systems for more dynamic freeze-drying of products with more precision in control.
In this blog, we take a close look at health equity in oncology trials specifically, assessing how the lack of diversity and inclusion has impacted cancer patients and the pharma industry’s key initiatives to address it. Learn more about how Clarify supports the real-world application of SDoH insights here. [1]
In an age of disruption, technology is key to enabling pharmaceuticalmanufacturers monitor, track and control shipments and their processes. Pharmaceutical firms are changing the way they do business; the future winners will be highly automated and digitalised.
Pierre Socha, partner at Amadeus Capital Partners, London, UK, predicts that larger pharmaceutical companies may have similar interests. Most pharmas will buy biotech companies or smaller pharma groups for the quality of their clinical assets and the drugs on their developments,” he says.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content